Neither side would say how long the arbitration might last. Massachusetts company Intellia Therapeutics and California 's Caribou Corporation are trying to resolve a complex CRISPR licensing dispute . In a filing from October 2018 , Intellia alleged Caribou violated a licensing agreement by attempting to license two patent families , developed using Intellia 's exclusive research into human therapeutics , to unnamed third parties . Caribou CEO Rachel Haurwitz said the licence was " specific to one specific technology " and not others .
Massachusetts company Intellia Therapeutics and California 's Caribou Corporation are trying to resolve a complex CRISPR licensing dispute . In a filing from October 2018 , Intellia alleged Caribou violated a licensing agreement by attempting to license two patent families , developed using Intellia 's exclusive research into human therapeutics , to unnamed third parties . Caribou CEO Rachel Haurwitz said the licence was " specific to one specific technology " and not others .